Navigation Links
Real-World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS(R) Express(TM) Stent
Date:3/29/2008

NATICK, Mass. and CHICAGO, March 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of two-year data from more than 7,000 patients in the TAXUS ARRIVE Registry program. The study was designed to evaluate the safety performance of the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System in patients treated in "real-world" practice. Outcomes through two years in the simple- use (single vessel/stent) patient group confirmed the favorable results seen in similar patients enrolled in previous TAXUS randomized clinical trials (the clinical trial cohort). Results in the more complex expanded-use group also continued the expected slightly higher event rates than simple-use patients, but were still favorable through two years compared to the published outcomes of other treatment modalities for such patients. Analysis of the data was presented by John M. Lasala, M.D., Ph.D., at the SCAI Annual Scientific Sessions in Partnership with the ACC/i2 Summit in Chicago.

"The extensive ARRIVE data show favorable and consistent outcomes in high- risk groups representing some of the most complex patients and lesions," said Dr. Lasala, Professor of Medicine, Washington University School of Medicine in St. Louis. "Outcomes in the simple-use patients in ARRIVE are consistent with results from the TAXUS Stent cohorts in the TAXUS randomized clinical trial program, indicating that the ARRIVE methodology is very efficient in capturing adverse event outcomes. Overall, then, these results support the long-term performance of the TAXUS Stent across the broad range of patients studied in these trials and registries."

The pooled analysis included two-year outcomes for 7,033 patients in t
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
2. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
3. GSK Receives Favorable Recommendation by FDA Advisory Committee for Rotarix(R) (Rotavirus Vaccine, Live, Oral)
4. Barr Announces Favorable Ruling in Yasmin(R) Patent Challenge
5. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
6. Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
7. Free CME-certified Webcast: Opening the Door to Better Myocardial Infarction Outcomes: Emergency Departments Hold the Key
8. UPDATE: Free CME-certified Webcast: Opening the Door to Better Myocardial Infarction Outcomes: Emergency Departments Hold the Key
9. Use of Fractional Flow for Optimizing Patient Outcomes is Topic of Several Sessions at TCT 2007
10. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
11. Patient-Reported Outcomes (PROs) Improve Cancer Treatment -- Experts Agree
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... difficult to manufacture proteins including biosimilar therapeutics, today ... for the second quarter ended June 30, 2014. ... initial public offering, we have the capital to ... from our proprietary protein expression platform," stated Bertrand ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... reported financial results for the six months ended ... expressed in Canadian dollars and presented under International ... 2014 Highlights , Announced top-line results ... primary endpoint for subjects enrolled in the Phase ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Intrinsic ... 13485:2003 certified, GAMP® 5 compliant imaging core lab, ... international Phase II clinical trial to assess a ... Throughout this trial, Intrinsic Imaging will provide comprehensive ... to, protocol and charter development, site qualification, site ...
(Date:8/28/2014)... Ind. A new research platform uses ... of tiny structures undergoing stress and heating, ... improve designs for microelectronics and batteries., This ... information about how heating and the surface ... properties. Researchers have discussed the merits of ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3
... N.Y. Researchers at Rensselaer Polytechnic Institute have ... of gold that measure only billionths of a ... equipment and works on nearly any surface including ... and semiconductor manufacturing. Sang-Kee Eah, assistant professor ...
... June 16 Trans World Alloys (TWA), one of the country,s ... Brennan has joined the company, as its new Chief Operating Officer. ACCORDING ... years experience in the metal business in a variety of areas." , ... Ed has attended the University of ...
... , , ... Thorne Ltd. (TSX-V: HTL), a leading provider of advanced laser systems and ... the launch of the Staccato(TM) multi-pulse laser system at the 8th Annual ... 16-19, 2010 , in San Francisco, CA. Staccato(TM) will add ...
Cached Biology Technology:Researchers develop ultra-simple method for creating nanoscale gold coatings 2Ed Brennan - New C.O.O. of Trans World Alloys 2Hamilton Thorne to launch Staccato(TM) laser at International Society of Stem Cell Research Annual Meeting 2Hamilton Thorne to launch Staccato(TM) laser at International Society of Stem Cell Research Annual Meeting 3Hamilton Thorne to launch Staccato(TM) laser at International Society of Stem Cell Research Annual Meeting 4
(Date:8/28/2014)... healthier for your neighbors than traditional cigarettes, but ... a new study from USC. , Scientists studying ... decrease in exposure to harmful particles, with close-to-zero ... to some harmful metals in second-hand e-cigarette smoke ... tobacco smoke contains high levels of polycyclic aromatic ...
(Date:8/28/2014)... MINNEAPOLIS/ST. PAUL (August 28, 2014) Researchers at the ... for facioscapulohumeral muscular dystrophy (FSHD) to be used for ... effectiveness of potential therapies for FSHD. , The research ... Cell Reports . , There is no treatment ... the most common type of muscular dystrophy. FSHD is ...
(Date:8/28/2014)... N.C. -- Scientists have identified the developmental on-off switch ... that produce more than two-thirds of the world,s naturally ... be to see whether it is possible to manipulate ... , The study, appearing August 28 in ... small molecule called cyclic-di-GMP and a larger protein called ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2UMN researchers find animal model for understudied type of muscular dystrophy 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... MINNETONKA, Minn., Feb. 8, 2011 MedNet Solutions, ... in clinical study management systems, is pleased to ... the company,s flagship eClinical solution.  The ENLIGHTEN ... and easy-to-use electronic data capture (EDC) and clinical ...
... of the turtle world swimming farther, diving deeper and ... But for all their toughness, they have still suffered a ... Ocean over the last 20-plus years, largely at the hands ... tagging and tracking the turtles are providing insights into their ...
... their ability to exhibit the "Cheerios effect" when they move ... together like Cheerios swimming in milk in a cereal bowl ... has made Virginia Tech engineers speculate about the possible impacts ... the journal, Soft Matter , a publication of the ...
Cached Biology News:MedNet Solutions Announces Significant Enhancements to ENLIGHTEN, Its Flagship EDC / eClinical Solution 2Why leatherback turtles linger in South Pacific Gyre, and why it matters 2Why leatherback turtles linger in South Pacific Gyre, and why it matters 3Why leatherback turtles linger in South Pacific Gyre, and why it matters 4When worms stick together and swim on thin water, what happens and why does it matter? 2
... choice of PDMS Stamps (3 PDMS micropatterned ... micron squares or 100 um x 10 ... lines, 3 PDMS nano-patterned stamps with depth ... pitch of 400 nm, or 3 PDMS ...
Request Info...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
Request Info...
Biology Products: